成大生物2025年度归母净利润1.38亿元，同比下降59.86%

Core Viewpoint - Chengda Biotech (688739.SH) reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the domestic rabies vaccine market and strategic adjustments in R&D [1] Group 1: Financial Performance - The company achieved an operating revenue of 1.39 billion yuan, a year-on-year decrease of 17.06% [1] - The net profit attributable to the parent company was 138 million yuan, reflecting a year-on-year decline of 59.86% [1] Group 2: Factors Affecting Performance - The decline in operating revenue was primarily due to changes in the domestic human rabies vaccine market, influenced by regulatory policy changes and intensified market competition, leading to reduced market demand [1] - Increased asset impairment losses were mainly due to the company's strategic adjustment in R&D, resulting in the termination of the hib vaccine project and full impairment of capitalized R&D investments related to that project [1] - The increase in fair value gains was attributed to the recovery in asset valuations within the innovative drug sector of the private equity funds the company invested in [1] - The company experienced growth in overseas sales revenue and managed to mitigate some downward pressure on performance through effective control of sales and management expenses [1]